TLR7 and neoplasm: In Liu et al.’s study, a MUC1 vaccine combined with TLR7 agonist demonstrated significant immune activation and anti-tumor effects in a mouse model of breast cancer, enhancing immune response against MUC1-expressing tumor cells (166).